Nasdaq: EIKN · Listed Feb 5, 2026
Eikon Therapeutics IPO
IPO price
$18.00
Eikon Therapeutics (EIKN) priced its IPO at $18.00 a share and has traded on Nasdaq since Feb 5, 2026.
EIKN today$5.17-71.28%since IPO15-min delayed · as of 7:30:02 PM EST on Nov 18, 2026
See the EIKN quoteFirst trading day · Feb 5, 2026
- IPO price
- $18.00
- the top of the range of $16 to $18
- First trade
- $17.05
- -5.28% from the IPO price
- First-day last trade
- $14.81
- -17.72% from the IPO price, regular session
- Raise
- $381.2M
- before the underwriters' option
These numbers are from the first trading day, Feb 5, 2026.
How EIKN did against the market
EIKN against the market, from its first trade at 12:40 ET to the last trade of the session.
- EIKN from its first trade
- -13.14%
- Against the market (QQQ)
- -12.4 pts
EIKN fell 13.1% from its first trade to the last trade of the session. That is 12.4 points worse than the market.
Same-day moves do not show that EIKN caused them. The market is QQQ, the Nasdaq-100 ETF.
The debut race
EIKN against other big listings, as the percent change from each stock's own IPO price.
The first 30 trading days. Each point is the last regular-session trade of a day.
The first trading day.
The first trading day.
The IPO scoreboard
EIKN against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.
| IPO | Raised | First trade | Day 1 close | Day 1 close, as a bar | Day 5 | Day 30 |
|---|---|---|---|---|---|---|
| Eikon Therapeutics '26 | $381.2M | -5.28% | -17.72% | -19.06% | -39.17% | |
| Figma '25 | $1.22B | +157.58% | +252.42% | +173.64% | +69.64% | |
| Circle '25 | $1.05B | +122.58% | +168.45% | +278.18% | +622.98% | |
| Reddit '24 | $748M | +38.24% | +47.97% | +69.90% | +40.32% | |
| Arm '23 | $5.23B | +10.00% | +23.76% | +3.63% | -3.06% | |
| Klarna '25 | $1.37B | +30.00% | +16.14% | +13.73% | -7.33% | |
| CoreWeave '25 | $1.5B | -2.50% | +0.02% | +34.32% | +28.42% |
Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.
The offering
The Eikon Therapeutics IPO offers 21.18M shares to raise $381.2M, before any underwriters' option.
- Expected price range
- $16 to $18
- IPO price
- $18.00
- Shares offered
- 21.18M
- Money raised
- $381.2M
- Listing date
- Feb 5, 2026
- Exchange
- Nasdaq
- Security
- Ordinary Shares
Money raised, against the largest IPOs
- Alibaba '14$21.77B
- Facebook '12$18.41B
- Rivian '21$11.93B
- Uber '19$8.1B
- Arm '23$5.23B
- Eikon Therapeutics$381.2M
Where EIKN ranks
Eikon Therapeutics's market cap against the largest US-listed companies.
Market cap, against the largest US-listed companies
- AAPL$5.12T
- MSFT$3.77T
- NVDA$3.65T
- GOOGL$3.47T
- AMZN$2.9T
- TSM$1.88T
- AVGO$1.69T
- META$1.58T
- TSLA$1.52T
- BRK.B$1.22T
- EIKN$280.14M
EIKN news
The latest news and headlines about Eikon Therapeutics (EIKN).
- Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology CongresspositiveGlobeNewswire Inc.· Oct 26, 2026
- Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology CongresspositiveGlobeNewswire Inc.· Oct 18, 2026
- Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical OncologypositiveGlobeNewswire Inc.· May 30, 2026
Filings and the company
What Eikon Therapeutics has disclosed to the SEC, and the basic facts about the listing.
8-K filings
Material events that Eikon Therapeutics discloses to the SEC on Form 8-K.
- Quarterly earningsNov 12, 2026
On November 12, 2026, Eikon Therapeutics, Inc. issued a press release announcing clinical and corporate updates and its financial results for the quarter ended September 30, 2026 (the "Press Release").
- Clinical trial resultsOct 26, 2026
Among participants in the squamous cohort, an ORR of 72.4% and a DCR of 100% were observed, respectively, with a median follow-up of 12.7 months and a median duration of response (DOR) of 12.9 months at the efficacy data cutoff. Among participants in the non-squamous cohort, an ORR of 55.6% and a DCR of 80.6% were observed, respectively, with a median follow-up of 17.9 months.
- Clinical trial resultsOct 23, 2026
“On October 23, 2026, the Company presented initial and updated data for EIK1003 and initial data for EIK1004 and EIK1005 at the 2026 European Society for Medical Oncology Congress.” The filing reports safety, tolerability, pharmacokinetic, objective response, disease-control, and duration-of-response data from multiple Phase 1/2 clinical trial cohorts.
- Investor presentationAug 14, 2026
On August 13, 2026, Eikon Therapeutics, Inc. updated its corporate presentation. A copy of the updated presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
- Director departureAug 3, 2026
Effective July 31, 2026, Leon Chen, Ph.D. and Joshua Wolfe resigned from the Board of Directors of Eikon Therapeutics, Inc. (the "Company"). Dr. Chen's and Mr. Wolfe's resignations were not because of a disagreement with the Company on any matter relating to the Company's operations, policies or practices.
About Eikon Therapeutics
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
- Ticker
- EIKN
- Exchange
- Nasdaq
- Market
- stocks
- Type
- CS
- Currency
- USD
- Industry
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Employees
- 384
- Listed
- Feb 5, 2026
- Security
- Ordinary Shares
Frequently asked questions
What was the Eikon Therapeutics IPO price?
$18.00 a share.
When did Eikon Therapeutics go public?
Eikon Therapeutics listed on Nasdaq on Feb 5, 2026 under the ticker EIKN.
How much did the Eikon Therapeutics IPO raise?
$381.2M, before any underwriters' option.
How did Eikon Therapeutics open on its first day?
EIKN first traded at $17.05, -5.28% from the IPO price of $18.00.
How did EIKN close on its first day?
Its last regular-session trade was $14.81, -17.72% from the IPO price of $18.00.
What was the EIKN first-day trading range?
$14.37 to $17.40 in the regular session.
How many EIKN shares traded on the first day?
4.41M shares in the regular session.
How many shares did Eikon Therapeutics sell in its IPO?
21.18M shares.
How did EIKN do against the market on its first day?
EIKN fell 13.1% from its first trade to the last trade of the session. That is 12.4 points worse than the market (QQQ, the Nasdaq-100 ETF).
What exchange is EIKN listed on?
Eikon Therapeutics lists on Nasdaq under the ticker EIKN.
Build with Massive
Get the EIKN data behind this page
| What the page shows | Endpoint |
|---|---|
| Offering terms and dates | /vX/reference/ipos |
| Price | /v3/snapshot |
| Chart, VWAP, and the market comparison | /v2/aggs/ticker/EIKN/range/5/minute |
| Market cap | /v3/reference/tickers/EIKN |
| News | /v2/reference/news |
| Filings | /vX/disclosures |
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.